What is Klaria?
Klaria, established in 2014 and headquartered in Uppsala, Sweden, is a pharmaceutical company specializing in a patented drug delivery platform. This innovative technology utilizes an alginate-based polymer film, designed to enhance the efficacy and delivery of therapeutic agents. The company's focus on novel delivery systems positions it within the competitive landscape of pharmaceutical innovation.
How much funding has Klaria raised?
Klaria has raised a total of $5.8M across 1 funding round:
Private Equity
$5.8M
Private Equity (2021): $5.8M with participation from Modelio Equity
Key Investors in Klaria
Modelio Equity
Modelio Equity is a Swedish financial firm registered with the Swedish Financial Supervisory Authority, specializing in investments and managing a portfolio of listed companies. Their involvement indicates a strategic interest in established or growth-stage companies.
What's next for Klaria?
The recent major strategic investment suggests Klaria is poised for significant scaling and market penetration. This capital infusion is likely to accelerate the development and commercialization of its proprietary drug delivery technology. Future growth will probably involve expanding its product pipeline, forging strategic partnerships, and potentially seeking further financing rounds to support global expansion and regulatory approvals.
See full Klaria company page
